November 23, 2022

Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference

ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today it will participate in the 34th Annual Piper Sandler Healthcare Conference on December 1, 2022. William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial Officer, will take part in a fireside chat at 9:30 a.m. EST, as well as one-on-one… Read More
learn more
November 17, 2022

Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting

Health economics and outcomes research showed post-Stupp therapeutic developments, including TTFields, significantly increase overall survival in a large commercially insured population The largest safety dataset to date of more than 23,000 patients reinforced that TTFields therapy is well-tolerated in patients with high-grade gliomas ROOT, Switzerland–(BUSINESS WIRE)–Novocure… Read More
learn more
November 15, 2022

Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada

Novocure chose Montreal because of its innovative culture, world-class universities and hospitals, access to top talent and quality of life ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced it has opened a new office in Montreal to expand and support its growing business in Canada. Novocure is a global… Read More
learn more
November 11, 2022

Novocure Secures CE Mark for New Array

New arrays are lighter, thinner and more flexible than current commercial arrays and have the potential to optimize Tumor Treating Fields dose ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced receipt of CE Mark for its new polymer-based transducer array, called the flex array, designed for more efficient Tumor… Read More
learn more